On Wednesday, Shares of Itaú Unibanco Holding S.A. (NYSE:ITUB), lost -2.26% to $10.80.
Corpbanca climbed to a seven-month high after Brazil’s Itau Unibanco Holding SA agreed to sweeten terms of the merger of its Chilean unit with the lender controlled by billionaire Alvaro Saieh, according to Bloomberg.
Corpbanca’s shareholders will vote June 26 on an extraordinary $400 million dividend as part of its deal with Itau, according to a filing posted Tuesday on the website of Chile’s securities regulator. The dividend would compensate for a drop in profitability at Itau Chile since the agreement was signed in January 2014.
Itau had offered a $300 million extra dividend to speed up the approval process and compensate for the reduced value of its Chilean unit, while Corpbanca’s board had asked for $400 million and other consideration. The offers and counteroffers had sparked speculation that talks were floundering and the deal could fall apart, Catalan said.
Corpbanca and Itau Chile also agreed to postpone the merger deadline until next year, with each lender paying half of their 2015 profit as dividends. Bloomberg Reports.
Itaú Unibanco Holding S.A. provides various financial products and services to individuals and corporate clients in Brazil and internationally. The company operates through Commercial Bank Retail, Consumer Credit Retail, and Wholesale Bank segments.
Shares of Exxon Mobil Corporation (NYSE:XOM), declined -0.22% to $84.95, during its last trading session, as oil prices fell in trading yesterday.
Industry standard Brent crude for July delivery was down 2.43% to $63.90 per barrel, while West Texas crude for July delivery was down 2.56% to $59.69 in trading yesterday.
The fall in oil prices comes despite the fifth straight week of declining U.S. crude supplies in an already oversupplied market.
Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, counting olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products.
At the end of Wednesday’s trade, Shares of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX), gained 0.67% to $14.29.
Allscripts Healthcare Solutions, declared East Kent Hospitals University NHS Foundation Trust and Maidstone and Tunbridge Wells NHS Trust have each signed a contract to deploy Allscripts PASTM. The Allscripts PAS will replace the Trusts` existing system and will empower the originations to use a highly flexible and configurable solution to manage patient data. Allscripts PAS is used across the National Health Service (NHS) in more than a dozen trusts and hospitals.
These deployments reflect Allscripts continued expansion and progress in the UK. Last month, the company was awarded a place on the NHS SBS Clinical Information Systems Framework. The Framework can assist NHS Trusts by providing access to critical technology like the solutions Allscripts` offer, reducing procurement costs and enabling the NHS Trusts to localize their requirements. Allscripts was named in five of the six SBS categories.
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. It operates in three segments: Clinical and Financial Solutions, Population Health, and Managed Services.
Finally, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), ended its last trade with 5.95% surge, and closed at $5.88.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, declared that the European Commission has approved RELISTOR(R) (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The decision effective May 27, 2015 is applicable to all 28 European Union member states plus Iceland and Norway and comprises an additional one year of marketing protection. The European Commission decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which cited that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
RELISTOR was first approved in Europe in 2008 for the treatment of OIC in advanced illness patients, and is presently approved in more than 50 countries counting the United States.
Mark Baker, Chief Executive Officer of Progenics, stated, “This approval represents a milestone for the RELISTOR franchise, significantly expanding the number of patients in Europe who can benefit from this drug. OIC can be a tremendous burden, affecting a patient’s ability to function adequately, but RELISTOR provides patients with the ability to effectively treat their symptoms. Importantly the European approval also recognized the benign safety profile of RELISTOR.”
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
